Effect naproxen sulindac blood pressure response Twenty-eight patients mild essential hypertension atenolol five-week double-blind placebo-controlled trial effects sulindac naproxen blood pressure BP control Atenolol weeks Naproxen sulindac atenolol week crossover week Data patients skin rash Naproxen systolic BP placebo mean mm Hg percent confidence interval significant differences systolic BP sulindac administration placebo naproxen significant effects diastolic BP Weight naproxen sulindac placebo mean kg significant extent One-week therapy naproxen potential sulindac systolic BP well-controlled hypertensive patients atenolol increase minor unlikely clinical significance 